ReviewThe EMBO journal2015
Transcription factor-mediated reprogramming toward hematopoietic stem cells.
Review in The EMBO journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Methylation profile of individuals with sickle cell trait.Epigenetics · 2025Pooled it
- Harnessing Lessons from Gel-Based and Advanced Biomaterial Therapeutics to Enable Direct Cellular Reprogramming.Gels (Basel, Switzerland) · 2026Review
- Review
- The functional interplay of transcription factors and cell adhesion molecules in experimental myelodysplasia including hematopoietic stem progenitor compartment.Molecular and cellular biochemistry · 2021Article
- Restoring aged stem cell functionality: Current progress and future directions.Stem cells (Dayton, Ohio) · 2020Review
- PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia-initiating cells.Blood · 2019Article
- Regnase-1-mediated post-transcriptional regulation is essential for hematopoietic stem and progenitor cell homeostasis.Nature communications · 2019Article
- BRWD1 orchestrates epigenetic landscape of late B lymphopoiesis.Nature communications · 2018Article
- Suppression of mCell research · 2018Article
- A CLK3-HMGA2 Alternative Splicing Axis Impacts Human Hematopoietic Stem Cell Molecular Identity throughout Development.Cell stem cell · 2018Article
- Dissecting BMP signaling input into the gene regulatory networks driving specification of the blood stem cell lineage.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Article
- Reprogramming mouse fibroblasts into engraftable myeloerythroid and lymphoid progenitors.Nature communications · 2016Article
- Progress towards generation of human haematopoietic stem cells.Nature cell biology · 2016Review
- Asynchronous combinatorial action of four regulatory factors activates Bcl11b for T cell commitment.Nature immunology · 2016Article
- Concise review: programming human pluripotent stem cells into blood.British journal of haematology · 2016Review
- Drug delivery, cell-based therapies, and tissue engineering approaches for spinal cord injury.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Progress and obstacles towards generating hematopoietic stem cells from pluripotent stem cells.Current opinion in hematology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
De novo generation of human hematopoietic stem cells (HSCs) from renewable cell types has been a long sought-after but elusive goal in regenerative medicine. Paralleling efforts to guide pluripotent stem cell differentiation by manipulating developmental cues, substantial progress has been made recently toward HSC generation via combinatorial transcription factor (TF)-mediated fate conversion, a paradigm established by Yamanaka's induction of pluripotency in somatic cells by mere four TFs. This review will integrate the recently reported strategies to directly convert a variety of starting cell types toward HSCs in the context of hematopoietic transcriptional regulation and discuss how these findings could be further developed toward the ultimate generation of therapeutic human HSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.